FindTrial
Sign In

Exploratory research of biomarkers associated with NEXUS study

Biomarkers exploratory research accompanying A Multicenter Phase II Clinical Study Evaluating the Efficacy and Safety of Neoadjuvant and Adjuvant Chemotherapy with Encorafenib, Binimetinib Plus Cetuximab in Patients with Surgically Resectable BRAF V600E Mutant Colorectal Metastasis - NEXUS-Study-TR study

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000050149
Enrollment
44
Registered
2023-01-27
Start date
2022-09-13
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with surgically resectable BRAF V600E mutant colorectal metastasis.

Interventions

None listed

Sponsors

National Caner Cednyter Hosipital East
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with resectable metastatic colorectal cancer with BRAF V600E mutations enrolled in the NEXUS study are eligible.

Exclusion criteria

Exclusion criteria: Patients enrolled in the NEXUS study who indicated their intention to refuse to participate in this research

Design outcomes

Primary

MeasureTime frame
Overrall Survaival—

Secondary

MeasureTime frame
Progression Free Survial, Disease-Free Survial—

Countries

Japan

Contacts

Public ContactShin Kobayashi

National Cancer Center Hospital East Department of Hepatobiliary and Pancreatic Surgery

nexus_core@east.ncc.go.jp0471331111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026